Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 4,400 shares of the business’s stock in a transaction that occurred on Tuesday, June 26th. The shares were sold at an average price of $40.31, for a total value of $177,364.00. Following the completion of the sale, the chief executive officer now directly owns 812,613 shares in the company, valued at approximately $32,756,430.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Atara Biotherapeutics opened at $36.75 on Friday, Marketbeat Ratings reports. Atara Biotherapeutics Inc has a twelve month low of $12.65 and a twelve month high of $54.45. The firm has a market cap of $1.59 billion, a PE ratio of -9.19 and a beta of 2.61.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.13). research analysts forecast that Atara Biotherapeutics Inc will post -4.06 EPS for the current fiscal year.
Institutional investors have recently bought and sold shares of the company. Riverhead Capital Management LLC purchased a new stake in shares of Atara Biotherapeutics during the first quarter worth $100,000. SG Americas Securities LLC purchased a new stake in shares of Atara Biotherapeutics during the first quarter worth $107,000. Principal Financial Group Inc. purchased a new stake in shares of Atara Biotherapeutics during the first quarter worth $214,000. Teacher Retirement System of Texas purchased a new stake in shares of Atara Biotherapeutics during the first quarter worth $260,000. Finally, Wasatch Advisors Inc. purchased a new stake in shares of Atara Biotherapeutics during the first quarter worth $395,000. 98.37% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have issued reports on ATRA shares. Zacks Investment Research lowered Atara Biotherapeutics from a “buy” rating to a “sell” rating in a research report on Thursday, May 10th. JPMorgan Chase & Co. started coverage on Atara Biotherapeutics in a research report on Tuesday, April 10th. They issued an “overweight” rating and a $56.00 target price on the stock. ValuEngine raised Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. William Blair reissued an “outperform” rating on shares of Atara Biotherapeutics in a research report on Tuesday, March 20th. Finally, Jefferies Financial Group boosted their target price on Atara Biotherapeutics from $30.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, March 5th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $43.33.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.